Compounding Pharmacy Market to Reach $21.01 Billion by 2031

The compounding pharmacy market is expected to reach $21.01 billion by 2031, up from $15.48 billion in 2026. The market is projected to grow at a compound annual growth rate (CAGR) of 6.3% during the forecast period.

The market's expansion is attributed to several factors, including an increasing emphasis on safety for ready-to-administer (RTA) and standardized doses, alongside a growing trend toward personalized dosages. Additionally, ongoing demand for GLP-1 drugs has created a supply gap, further boosting the compounding pharmacy sector.

North America held the largest market share in 2025, accounting for approximately 43.5%. Oral drugs constituted the largest product segment, representing about 33.4% of the market. The pharmaceutical dosage alteration segment is forecast to be the fastest-growing, with a projected CAGR of 7.1%.

Adult patients represented the dominant end-user segment in 2025, holding a 58.3% share. Hormone replacement therapy is anticipated to emerge as the fastest-growing therapeutic application by 2031, reflecting the rising demand for individualized treatment options.